Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.
L, R., J, C., H, L., J, X., W, F., D, Y., F, L., Y, L., & L, J. (2026). Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.. Current oncology (Toronto, Ont.). https://doi.org/10.3390/curroncol33070402
L R, J C, H L, J X, W F, D Y, et al. Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.. Current oncology (Toronto, Ont.). 2026; doi: 10.3390/curroncol33070402
L R, J C, H L, et al. Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.[J]. Current oncology (Toronto, Ont.). 2026. DOI: 10.3390/curroncol33070402.
@article{l2026,
author = {Ran L and Chen J and Liang H and Xie J and Fu W and Yang D and Li F and Liu Y and Jiang L},
title = {Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting.},
journal = {Current oncology (Toronto, Ont.)},
year = {2026},
doi = {10.3390/curroncol33070402},
note = {PMID: 42505204},
}
TY - JOUR AU - Ran L AU - Chen J AU - Liang H AU - Xie J AU - Fu W AU - Yang D AU - Li F AU - Liu Y AU - Jiang L TI - Incremental Value of Iodine-125 Seed Implantation After Bronchial Artery Chemoembolization in Immunotherapy-Treated Advanced Lung Squamous Cell Carcinoma with Hemoptysis: A Retrospective Cohort Study Using Inverse Probability of Treatment Weighting. T2 - Current oncology (Toronto, Ont.) PY - 2026 DO - 10.3390/curroncol33070402 AN - PMID:42505204 ER -
BACKGROUND: The incremental value of iodine-125 (I-125) seed implantation in advanced refractory lung squamous cell carcinoma (LUSC) with hemoptysis treated with bronchial artery chemoembolization (BACE) and immunotherapy remains unclear. METHODS: This retrospective cohort study included 90 patients treated between June 2023 and June 2025. Patients receiving BACE plus immunotherapy were classified according to whether I-125 seed implantation was performed within 7 days after BACE: G1, BACE plus immunotherapy (n = 42), and G2, BACE, I-125 seed implantation, and immunotherapy (n = 48). Inverse probability of treatment weighting (IPTW) served as the primary adjustment method. RESULTS: After IPTW, baseline covariates were well balanced; propensity score matching yielded 26 patients per group. Compared with G1, G2 was associated with longer hemoptysis-free survival (not reached vs. 11 months; HR = 0.34, 95% CI 0.18-0.64, p < 0.05), overall survival (19 vs. 14 months; HR = 0.26, 95% CI 0.15-0.44, p < 0.05), and progression-free survival (12 vs. 9 months; HR = 0.34, 95% CI 0.21-0.56, p < 0.05). The 6-month objective response rate (ORR) and disease control rate (DCR) were higher in G2, whereas no significant difference in 24-h hemostasis or recorded grade 3 or higher adverse events was observed. CONCLUSIONS: Adding I-125 seed implantation to BACE plus immunotherapy was associated with improved outcomes in selected patients, and prospective validation is warranted.